STNM 01

Drug Profile

STNM 01

Alternative Names: STNM-01

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stelic Institute & Co
  • Developer Sameshima Hospital; Stelic Institute & Co
  • Class Anti-inflammatories; Antifibrotics; Antiulcers
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 08 Dec 2017 3288368 - updaedd KDM, TT sec, PD sec and HE (assumed PD data, not very sure)
  • 09 Nov 2017 Stelic Institute completes a phase I clinical trial for Ulcerative colitis and Crohn's disease (Treatment-experienced) in Japan (Submucosal) (UMIN000020900; 9226074)
  • 28 Oct 2017 Efficacy and pharmacodynamic data from a phase IIa trial in Ulcerative colitis presented at the 25th United European Gastroenterology Week (UEGW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top